NIP-22c
NIP-22c is a novel coronavirus 3CLpro inhibitor. The EC50 for Verona, Calu3, Caco2 and HBTEC-ALI were 4.6, 1.1, 0.1 and 0.6 μM, respectively. NIP-22c has antiviral activity.
For research use only. We do not sell to patients.
- CAS No.: 2309384-85-6
- Formula: C32H39N5O6
- Molecular Weight:589.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | CC50 |
>100 μM
Compound: 22c
|
Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability
Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability
|
[PMID: 38432056] |
| Calu-3 | CC50 |
>100 μM
Compound: 22c
|
Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability
Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability
|
[PMID: 38432056] |
| CCRF-CEM | CC50 |
13.9 μM
Compound: 22c
|
Cytotoxicity against human CEM cells assessed as reduction in cell viability
Cytotoxicity against human CEM cells assessed as reduction in cell viability
|
[PMID: 38432056] |
| Huh-7 | CC50 |
32.7 μM
Compound: 22c
|
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability
|
[PMID: 38432056] |
| PBMC | CC50 |
30.9 μM
Compound: 22c
|
Cytotoxicity against human PBMC cells assessed as reduction in cell viability
Cytotoxicity against human PBMC cells assessed as reduction in cell viability
|
[PMID: 38432056] |
| Vero | CC50 |
84.3 μM
Compound: 22c
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability
|
[PMID: 38432056] |
Chemical Information
-
CAS No. 2309384-85-6
-
Molecular Weight 589.68
-
Formula C32H39N5O6
-
SMILES
O=C(N[C@@H](CC(C)C)C(N[C@@H](C[C@@H]1CCCNC1=O)C=O)=O)[C@@H](NC(C2=NOC(C)=C2)=O)CC3=CC=CC4=C3C=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)